Secondary Hemophagocytic Lymphocytosis in Inflammatory Bowel Disease
Jacob Boccucci, Ramalakshmi Thulluri, Chandini Kannan, Matthew Gold, Vamsi Kota
TL;DR
This paper reports a rare case of hemophagocytic lymphohistiocytosis in an inflammatory bowel disease patient without a concurrent viral infection.
Contribution
The novelty is presenting a case of HLH linked to thiopurine use in IBD without EBV infection.
Findings
HLH occurred in a patient treated with azathioprine for IBD.
No concurrent Epstein–Barr virus infection was present in this case.
Abstract
Background and Clinical Significance: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition that can go underdiagnosed due to overlapping features with severe infections. While the use of thiopurine in inflammatory bowel disease (IBD) has been associated with HLH, the majority of these patients will have a concurrent Epstein–Barr virus (EBV) infection. Case Presentation: This report presents a case of HLH in a patient previously treated with aza-thioprine for IBD without concurrent viral infection.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAutoimmune and Inflammatory Disorders Research · Immune Cell Function and Interaction · Adolescent and Pediatric Healthcare